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1063-4584/Crown Copyright © 2015 Published by ElsIt is a decade since genetically-modiﬁedmice, deﬁcient in either
ADAMTS-4 or ADAMTS-5, were used to identify ADAMTS-5 as the
primary aggrecanase in models of inﬂammatory1 and non-inﬂam-
matory2 joint disease. However, the identity of the human aggreca-
nase has been less clear, with evidence on both sides of the debate
informing the interim consensus that ADAMTS-4 and ADAMTS-5
might each play important roles in human aggrecanolysis. Using
monoclonal antibodies (mAbs) that target the same structural do-
mains within ADAMTS-4 and ADAMTS-5, Larkin and colleagues
now describe anti-ADAMTS-5 mAbs that block aggrecan loss from
cartilage in humans ex vivo, and non-human primates in vivo, and
inhibit structural damage and mechanical allodynia in mouse
models of OA3. The authors used ARGS neoepitope as a readout
for ADAMTS-mediated aggrecan loss, to show that ADAMTS-5
mAbs were more effective than ADAMTS-4 or isotype control
mAbs at reducing ARGS release from human cartilage explants in
unstimulated conditions. Similarly, the levels of circulating ARGS
epitope in cynomolgus monkeys that naturally develop an OA-
like condition, were reduced by treatment with ADAMTS-5 mAbs
and remained low following twice-monthly antibody administra-
tion. Although the release of ARGS from human cartilage explants
was not inhibited by ADAMTS-4 mAbs in unstimulated conditions,
in the presence of cytokine stimulation, ADAMTS-4 and ADAMTS-5
mAbs slowed release of ARGS neoepitope suggesting that both
enzymes might have a role under certain conditions. This study
advances OA research in several important directions.
New insights into the structureefunction relationship of the
catalytic and disintegrin-like domains of ADAMTS-5
One key ﬁnding is that the most effective ADAMTS-5mAb is one
that targets a conformational epitope spanning both the catalytic
and the disintegrin-like domains. ADAMTS-5 mAbs targeting the
catalytic site alone were ineffective inhibitors. The authors proposeevier Ltd on behalf of Osteoarthritthat inhibition induced by targeting both the catalytic and
disintegrin-like domains might arise via an allosteric lock mecha-
nism. This hypothesis is consistent with original reports of the
ADAMTS-5 crystal structure showing that the catalytic and
disintegrin-like domains form a single folding unit, and exist in
both open and closed conﬁgurations4. The present results provide
the ﬁrst example within the metzincin family of targeting enzyme
inhibition beyond the catalytic domain. Further investigation of
the structureefunction relationship between the catalytic and
disintegrin-like domains of ADAMTS-5 are warranted.
Evidence that therapies designed to treat structural damage in
joints might also ameliorate pain
Although it is pain that brings the patient to the physician, it is
structural damage that leads to disability and failure of the joint.
However the relationship between pain, and structural damage to
joint tissues, is unclear. Malfait and colleagues have previously
shown that ADAMTS-5 deﬁcient mice fail to develop mechanical
allodynia (a pain-related behaviour) associated with experimental
OA5. Larkin and colleagues analysed the effect of treating mice
with ADAMTS-5 mAbs prophylactically, and for 8-weeks post
DMM surgery; they found that the mice were protected from me-
chanical allodynia during this time. This result appears to link
structural damage with pain and provides the ﬁrst tantalising evi-
dence that therapies designed to treat joint structural damage
might also have efﬁcacy in ameliorating OA-related pain. The
mechanisms underlying this relationship have yet to be fully
explored, but are now possible with the availability of ADAMTS-4
and ADAMTS-5 mAbs.
Treatment with ADAMTS-5 mAbs post-DMM surgery might
promote cartilage accrual
Histological analyses of cartilage damage in the mouse DMM
model showed that not only did prophylactic administration of
ADAMTS-5 mAbs prevent aggrecan loss and cartilage erosion, but
that mice continuing to receive weekly treatments over an
8-week period appeared to accrue cartilage. Although this remark-
able and unprecedented observation requires further investigation
and quantitation, it does raise the possibility that ADAMTS-5 mAbs,
at doses equal to or less than those reported by Larkin et al., might
have efﬁcacy as cartilage-promoting as well as cartilage-sparing
agents in certain clinical settings.is Research Society International. All rights reserved.
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Following intra-peritoneal injections into mice, labelled
ADAMTS-4 and ADAMTS-5 mAbs showed a systemic bio-
distribution and were readily detected in joint tissues when
mice were harvested 4 days later. High power images conﬁrmed
mAb penetration into knee cartilage with staining in the superﬁ-
cial zone and pericellular region of chondrocytes. These results
conﬁrm that the ADAMTS-4 and -5 mAbs reach their molecular
targets in joint tissues, and most likely in other tissues where
the effects of ablating ADAMTS-5 activity have yet to be tested.
Versican is a large aggregating proteoglycan, related to aggrecan,
and is also a substrate for ADAMTS-5. Proteolysis of versican is
essential in some developmental and homeostatic processes6.
For example, failure to remodel versican in cardiac valves during
development is associated with myxomatous valve disease7. In
atherosclerotic disease, ADAMTS-5 deﬁciency is thought to impair
proteolysis of versican and the small proteoglycan biglycan, and
contribute to lipoprotein retention in the aorta8 leading to athero-
sclerosis. Other studies suggest that ADAMTS-5 deﬁciency in
tendon disturbs organisation of the tendon matrix and adversely
affects its biomechanical properties9. Assessing the safety and
tolerability of the ADAMTS-5 mAbs (GSK2394002) in other tissues
is the next priority for Larkin and colleagues, ahead of clinical tri-
als in OA patients.
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